Purpose: This study was conducted to evaluate the effect of DA-6034, a potent secretagogue, on aqueous tear fluid secretion and its quality in normal rabbit. We also evaluated, in animal models of experimentally induced dry eye disease, its effectiveness over time to stimulate aqueous tear production by ocular ferning test and goblet cell proliferation.
Methods: Aqueous tear production, total protein levels, and glycoprotein levels in normal rabbits were evaluated after topical application of DA-6034 (0.3, 1, and 3%). Moreover, time course aqueous tear volume measurement and ocular ferning test in tear fluid were performed in dry eyes of rabbits that had been given 1% atropine sulfate, topically. Altogether, tear fluid production and conjunctival goblet cell numbers were measured in dry eyes of mice that had been given topical scopolamine.
Results: Topical application of DA-6034 (0.3, 1, and 3%) significantly increased (P < 0.05) aqueous tear production in a concentration-dependent manner in normal rabbits. There was no change in total protein levels while glycoprotein levels were significantly increased (P < 0.05) at 3% DA-6034. The increase in aqueous tear fluid was significant (P < 0.05) and lasted for 2 h post-instillation in dry eyes of rabbits that had been given 1% atropine sulfate; 10-day repeated instillation of the drug in this model resulted in large and homogeneous fern-like tear patterns. In a mouse model, DA-6034 given as a 3% eyedrop solution significantly increased (P < 0.05) tear fluid production and conjunctival goblet cell number.
Conclusions: These results suggest that DA-6034 accelerates not only tear secretion but also mucin production and may be a potential therapeutic agent for the treatment of dry eye disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/jop.2008.0126 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical practice patterns in the management of dry eye disease: A TFOS international survey 2023-4.
Ocul Surf
December 2024
Centre for Ocular Research and Education (CORE), School of Optometry and Vision Science, University of Waterloo, Canada; Optometry and Vision Science Research Group, College of Health and Life Sciences, Aston University, Birmingham, United Kingdom; Department of Ophthalmology, Aotearoa New Zealand National Eye Centre, The University of Auckland, New Zealand.
Aims: To understand current clinical management of dry eye disease (DED), based on its perceived severity and subtype by practitioners across the world.
Methods: The content of the anonymous survey was chosen to reflect the DED management strategies reported by the Tear Film and Ocular Surface Society (TFOS) 2 Dry Eye Workshop (DEWS II). Questions were designed to ascertain practitioner treatment choice, depending on the subtype and severity of DED.
Blood component therapy for dry eye disease: a systematic review and network meta-analysis.
Front Med (Lausanne)
December 2024
Department of Ophthalmology, Zhangye People's Hospital Affiliated to Hexi University, Zhangye, China.
Objective: Blood component therapy has shown promising potential as an emerging treatment for dry eye disease; however, it remains unclear which specific blood component is the most effective. This study aims to compare the efficacy of different blood components in the treatment of dry eye disease through a network meta-analysis, with the goal of providing the latest and most reliable evidence for clinical practice.
Methods: We conducted a systematic search of the PubMed, Web of Science, Cochrane, Embase, and Scopus databases, with the search concluding on June 1, 2024.
Ocular toxicity, distribution, and shedding of intravitreal AAV-eqIL-10 in horses.
Mol Ther Methods Clin Dev
December 2024
Clinical Sciences, North Carolina State University, Raleigh, NC 27607, USA.
Non-infectious uveitis (NIU) is a painful recurrent disease affecting 2%-5% of horses. Current treatments require frequent administration with associated adverse events. In a previous study, intravitreal (IVT) adeno-associated virus (AAV) harboring equine interleukin-10 (eqIL-10) cDNA inhibited experimental uveitis in rats.
View Article and Find Full Text PDFEffects of systemic fingolimod treatment on anterior segment parameters and tear film functions.
Cutan Ocul Toxicol
December 2024
Department of Ophthalmology, Ankara Bilkent City Hospital, Ankara, Turkey.
Purpose: To investigate the potential effects of systemic fingolimod treatment on parameters of the anterior segment of the eye and tear film function tests in patients with multiple sclerosis (MS).
Methods: Forty-eight eyes of 24 individuals who were started on systemic fingolimod treatment for relapsing-remitting MS were prospectively enrolled in this study. Patients underwent examinations immediately before initiation of systemic fingolimod treatment, and at the first and sixth months of treatment.
Keratoconjunctivitis sicca in intact Aksaray Malakli breed dogs: Evaluation of 50 cases.
Vet Ophthalmol
December 2024
Faculty of Veterinary Medicine, Department of Biostatistics, Ankara University, Ankara, Turkey.
Article Synopsis
- The study focuses on keratoconjunctivitis sicca (KCS), a condition in dogs that leads to eye damage due to reduced tear production, particularly in Aksaray Malakli breed dogs.
- Researchers evaluated fifty healthy dogs showing signs of eye irritation and used tests to measure tear production and film stability.
- Results indicated that dogs with third eyelid gland prolapse had lower tear production and film stability, highlighting a need for further research to manage KCS in this breed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!